SCHEMBL3708900

SCHEMBL3708900

CCCCOC(=O)N1CC[C@@H](O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ DPP4 P27487 2/20 0.43
▸ GBA2 Q9HCG7 1/20 0.43
▸ GAA P10253 1/20 0.41
▸ DPP7 Q9UHL4 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ATM Q13315 2/20 0.39
▸ THRB P10828 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HRH2 P25021 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652388 1.00 LMNA (0.54) LMNAPOLBSMN1; SMN2DPP4GBA2
SCHEMBL3652385 1.00 LMNA (0.54) LMNAPOLBSMN1; SMN2DPP4GBA2
SCHEMBL3649934 0.91 POLB (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL30497646 0.91 POLB (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL3649936 0.91 POLB (0.51) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL184778 0.90 LMNA (0.61) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL1633241 0.86 LMNA (0.56) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL8260277 0.86 POLB (0.53) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL8260986 0.86 POLB (0.53) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL13175789 0.86 POLB (0.53) LMNAPOLBSMN1; SMN2GBA2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106146484-A Quinazoline derivant is as RAF kinase modulator and their method and purposes 埃姆比特生物科学公司 2016-11-23 — — CN disclosed
CN-102026985-B Quinazoline derivatives as RAF kinase modulators and methods and uses thereof 埃姆比特生物科学公司 2016-07-06 — — CN disclosed
WO-2010094643-A1 QUINOLINE DERIVATIVES AND THEIR USES FOR RHINITIS AND URTICARIA GLAXO GROUP LIMITED (GB) 2010-08-26 — — WO disclosed
US-7148242-B2 N-formyl hydroxylamine compounds, compositions and methods of use NOVARTIS AG (CH) 2006-12-12 — — US disclosed
EP-1401828-B1 N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF VICURON PHARM INC (US) 2006-04-12 — — EP disclosed
EP-1401828-A1 N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF Vicuron Pharmaceuticals, Inc. (US) 2004-03-31 — — EP disclosed
US-20030045479-A1 Novel N-formyl hydroxylamine compounds, compositions and methods of use VICURON HOLDINGS LLC 2003-03-06 — — US disclosed
WO-2002102790-A1 N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF VICURON PHARMACEUTICALS INC. (US) 2002-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045479-A1 Novel N-formyl hydroxylamine compounds, compositions and methods of use PDF, HNMT, AADAC LMNA 1749/4885POLB 249/4885SMN1; SMN2 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback